Halozyme Therapeutics Inc (HALO)

[Skeetz99]

Drug pipeline (in play and recent clinical results):

PEG20 - top WS analysts confirm that thromboembolic event rate issue is temporary and will be lifted (Piper Jaffray and BMO reconfirming encouraging feedback to resolve this issue going forward). Patients badly need Pancreatic treatments that work since there are very few options. So look for the FDA to make every effort to move this compound forward as survival data is very encouraging.
HyQvia - FDA decision (with Baxter) pending by early June (for US); already approved in Europe
MabThera SC - recently Approved in Europe; HALO earns a $10mm milestone payment
Herceptin SC Approved in Europe; HALO earns a $10mm milestone payment
Hylenex - recent clinical diabetes results were very good, in discussions with FDA regarding label change pending and future is very bright here.
HT501 - trial results for cellulite were very good; will start a US trial or sell compound to another interested party.
Enhanze technology - Pfizer has the option to select six possible compounds to use HALO Enhanze technology. Already received an $8mm up front payment.

Notes: Already generating $50mm in Revenue too. Recent stock offering raised $100mm (can buy other Oncology compounds already in trials so cash position is very strong. Lastly, HALO is a huge takeover target as well and the company could become profitable by this time next year or by the end of 2015.